| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lenalidomide | FIMM | pan-cancer | AAC | 0.036 | 0.8 |
| mRNA | hyperforin | CTRPv2 | pan-cancer | AAC | 0.0085 | 0.8 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | 0.0081 | 0.8 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | -0.0076 | 0.8 |
| mRNA | AZD0530 | FIMM | pan-cancer | AAC | -0.034 | 0.8 |
| mRNA | IPA-3 | GDSC1000 | pan-cancer | AAC | -0.0067 | 0.9 |
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | 0.0079 | 0.9 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | -0.0078 | 0.9 |
| mRNA | bafilomycin A1 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.9 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0072 | 0.9 |